Search the MBS

Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $859.80

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61612
• Next - Item 61622

Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $859.80

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61620
• Next - Item 61628

Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $859.80

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61622
• Next - Item 61632

Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $859.80

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61628
• Next - Item 61640

Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. (R)

Bulk bill incentive

Fee: $999.00 Benefit: 75% = $749.25 85% = $905.80

• Previous - Item 61632
• Next - Item 61644

Single rest myocardial perfusion study for the assessment of the extent and severity of non‑viable myocardium, with PET, if:

(a) the service is performed because the service to which item 61325 applies cannot be performed due to unavailability of thallous chloride 201 (Tl-201); and

(b) the patient has left ventricular systolic dysfunction and probable or confirmed coronary artery disease; and

(c) the service is performed in conjunction with a rest myocardial perfusion study using technetium-99m; and

(d) the service is requested by a specialist or a consultant physician; and

(e) the service is not associated with a service to which item 11704, 11705, 11707, 11714, 11729 or 11730 applies; and

(f) this service and item 61325 are applicable only twice each 24 months (R)

Item 61644 is a substitute item that may only be used during periods of national shortage of Tl-201. See IN.4.4 of explanatory notes to this Category for further information. 

Bulk bill incentive

Fee: $329.00 Benefit: 75% = $246.75 85% = $279.65

(See para IN.4.4, IR.4.2 of explanatory notes to this Category)

• Previous - Item 61640
• Next - Item 61646

Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. (R)

Bulk bill incentive

Fee: $999.00 Benefit: 75% = $749.25 85% = $905.80

• Previous - Item 61644
• Next - Item 61647

Whole body ⁶⁸Ga DOTA peptide PET study, if:
(a) a gastro entero pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or
(b) both:
(i) a surgically amenable gastro entero pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and
(ii) the study is for excluding additional disease sites (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $859.80

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61646
• Next - Item 61650